INTRODUCTION
============

Human skin color is determined mainly by the pigment melanin, which is produced by melanocytes in the epidermis. Melanin production is induced upon skin exposure to ultraviolet radiation, and it is transported to keratinocytes in a vesicle-mediated manner ([@b27-bt-26-282]). Two types of melanin, eumelanin and pheomelanin, are produced from L-tyrosine through a multi-step process. Eumelanin is a dark, brown-black insoluble polymer responsible for dark skin color ([@b27-bt-26-282]). The rate-limiting step in melanogenesis is the conversion of L-tyrosine into L-dihydroxyphenylalanine (L-DOPA) by tyrosinase ([@b17-bt-26-282]; [@b11-bt-26-282]). For cosmetic and pharmaceutical purposes, many tyrosinase-inhibiting agents have been developed to manage skin pigmentation, such as hydroquinone (1,4-dihydroxybenzene), arbutin, azelaic acid (1,7-heptanedi-carboxyilic acid), and others ([@b10-bt-26-282]). Even though their anti-pigmentation effects have been well-established, the risk of side effects has brought about hesitation for continuous use of tyrosinase inhibitors, as shown by the fact that hydroquinone formulations with concentrations over 1% have been banned in Europe ([@b10-bt-26-282]).

RNA interference (RNAi) was first discovered as an antiviral defense mechanism in the nematode *Caenorhabditis elegans* in which double-stranded RNAs (dsRNAs) trigger gene silencing of complementary mRNA sequences ([@b9-bt-26-282]). Thereafter, artificially synthesized short interfering RNAs (siRNAs) were observed to be processed in mammalian cells ([@b5-bt-26-282]). RNAi processing consists of several steps; siRNA generation by dsRNA cleavage by Dicer, assembly of siRNA with the RNA-induced silencing complex (RISC), separation of siRNA strands (the sense (passenger) and antisense (guide) strands), binding of the antisense strand to mRNA with a complementary sequence, and degradation of mRNA by Argonaute 2 (Ago2) ([@b8-bt-26-282]).

Structural features of siRNA have been studied for decades. The classical structure of siRNAs requires an appropriate duplex length, 3′ overhang, and asymmetrical structure. From a study in *Drosophila melanogaster*, the standard siRNA design was proposed to be dsRNAs of 21 nt sense/antisense strands forming a 19 base-pair (bp) dsRNA stem with 2 nt 3′ overhangs at both ends ([@b7-bt-26-282]). However, in mammalian cells, recent studies showed that non-canonical siRNA could be as effective as classical siRNAs or could even be improved by variations in length, symmetry, and overhang. siRNAs without 3′ overhang(s) ([@b4-bt-26-282]; [@b22-bt-26-282]; [@b2-bt-26-282]), and those longer ([@b15-bt-26-282]) or shorter ([@b3-bt-26-282]) than 19 bp were also effective in gene silencing in mammalian cells. Asymmetry in 3′ overhang structure, only at the antisense strand, resulted in better performance than symmetric siRNAs ([@b23-bt-26-282]).

For effective and specific knockdown of mRNA targets, rational design of siRNAs is critical. First generation algorithms for siRNA design were developed based on thermodynamic stability ([@b24-bt-26-282]), positional preference ([@b1-bt-26-282]; [@b21-bt-26-282]; [@b29-bt-26-282]), and uniqueness of the target sequence ([@b20-bt-26-282]). These studies suggested that functional siRNAs are asymmetrical in the stability of the duplex ends as seen by the unstable 5′ terminus of guide strands, and the fact that 5′ termini of guide strands prefer the bases A or U. Additionally, evaluation of target site accessibility between siRNA and mRNA is critical, and is calculated based on the energy required for opening the binding site and forming hybridization ([@b19-bt-26-282]; [@b28-bt-26-282]). To enhance prediction accuracy, second generation algorithms utilized new models with a large number of observations. They applied an artificial neural network model ([@b13-bt-26-282]) or a linear regression model ([@b25-bt-26-282]; [@b30-bt-26-282]; [@b14-bt-26-282]).

In this study, we took various conditions into account to design efficient human tyrosinase siRNAs. To maximize efficiency in siRNA design, we combined known criteria for evaluation using multiple siRNA design algorithms (*RNAxs*, *i-Score*, and *siRNA scales*): target site accessibility, GC content, relative thermodynamic stability at both ends, as well as other criteria. We further demonstrated the inhibitory effect of selected siR-NAs on melanin production in human melanoma cells.

MATERIALS AND METHODS
=====================

Combinatorial application of siRNA design algorithms and synthesis
------------------------------------------------------------------

For the mRNA sequence of human tyrosinase (*TYR*), the reference sequence (Refseq id NM_000372) from the NCBI nucleotide database was utilized. To evaluate target accessibility, the *RNAxs* design tool was used (<http://rna.tbi.univie.ac.at/cgi-bin/RNAxs/>). *RNAxs* combines known siRNA functionality criteria (asymmetry, self-folding, free-end) with RISC target site accessibility ([@b28-bt-26-282]). 272 siRNAs passed with default parameters (8 nt accessibility threshold; 0.01157, 16 nt accessibility threshold; 0.001002, self-folding energy; 0.9022, sequence asymmetry; 0.5, energy asymmetry; 0.4655, free end; 0.625) in all criteria and were ranked by score. *i-Score* and *siRNA scales* are based on a linear regression model and were trained using the Huesken dataset ([@b13-bt-26-282]). The *i-Score* (inhibitory--Score) algorithm calculates ΔG values of siRNA strands, dinucleotides at the 5′ and 3′ ends, the maximum GC stretch length and GC content (<http://www.med.nagoya-u.ac.jp/neurogenetics/i_Score/i_score.html/>) ([@b14-bt-26-282]). This algorithm identifies the preferred base for each nucleotide position by calculating the inhibition score (*i-Score*). Also, to improve score design accuracy, we selected less thermostable siRNAs with whole ΔG values ≥−34.6 kcal/mol ([@b14-bt-26-282]). *siRNA scales* calculates the stability of 5′ and 3′ ends and total GC content (<http://gesteland.genetics.utah.edu/siRNA_scales/index.html/>) ([@b18-bt-26-282]). We applied filters of the scores to be *i-Score* ≥65 and *siRNA scales* ≤30. All siRNAs for TYR were synthesized by Bioneer Inc. (Dajeon, Korea) as 21-mers with a 3′ overhang on the antisense strand. See [Table 1](#t1-bt-26-282){ref-type="table"} for the full list of siRNAs.

Cell culture
------------

The highly pigmented human melanoma cell line MNT-1 was kindly provided by Dr. Minsoo Noh (Seoul National University, School of Pharmacy). Cells were maintained in Minimal Essential Medium (MEM) supplemented with 20% fetal bovine serum (FBS), 10% Dulbecco's Modified Eagle Medium (DMEM), and gentamicin (50 μg/mL). Trypsin (0.25%) and ethylenediaminetetraacetic acid (EDTA) were purchased from Gigbco-BRL, and 20 mM HEPES was purchased from Sigma (St. Louis, MO, USA). Cells were maintained at 37°C in a humidified atmosphere of 5% CO~2~ in air.

siRNA transfection
------------------

Lipofectamine 2000 (11668-027, Invitrogen, Waltham, MA, USA) or DharmaFECT (T-2001-02, Thermo Scientific, Walltham, MA, USA) was used for cell transfection according to the manufacturer's protocol. 34 anti-Tyrosinase siRNAs and non-targeting siRNA were purchased from Bioneer Inc. Positive control siRNA was purchased from Santa Cruz (\#sc-36766, Santa Cruz, Dallas, TX, USA). MNT-1 cells were grown to 60% confluence and transfected with either Lipofectamine or DharmaFECT reagent depending on the protocol of manufacturer.

Immunoblot analysis
-------------------

MNT-1 cells were lysed with lysis buffer (20 mM tris pH 7.5, 5 mM EDTA, 10 mM Na~4~P~2~O~7~, 100 mM NaF, 2 mM Na~3~VO~4~, 1% NP-40, 1 mM PMSF, 10 μg/mL aprotinin, and 10 μg/mL leupeptin) and 15 μg of protein was subjected to SDS-PAGE, and transferred to nitrocellulose membrane. The membranes were incubated with an anti-tyrosinase antibody (\#sc-7834, Santa Cruz). The bands were visualized with a ChemiDoc imaging system (Bio-Rad, Hercules, CA, USA) and quantified by ImageJ software (ver. 1.44p, NIH, USA).

Measurement of melanin content
------------------------------

Melanin content was measured as described previously ([@b12-bt-26-282]) with some modifications. Briefly, MNT-1 cells were seeded onto 6-well plates (6×10^5^ cells/well) and transfected with siRNA. At 48 h and 168 h after transfection, cells were washed with phosphate-buffered saline (PBS) and harvested. After washing with PBS, cell pellets were dissolved in 1 mL of 1 N NaOH containing 10% DMSO and incubated for 1 h at 80°C. The absorbance of the solution was measured at 450 nm. Melanin content was calculated based on a standard curve obtained from synthetic melanin.

Cell viability test (XTT assay)
-------------------------------

The XTT assay (cat\# 11465015001, Roche, Pleasanton, CA, USA) was performed according to the Manufacturer's protocol. Briefly, 6×10^5^ MNT1 cells/well were plated in 6-well plates. On the next day, cells were transfected with individual siRNAs. After 24 h, cells were plated in 96-well microplates in quintuplicate, and then were additionally maintained for the indicated number of days. For XTT assay, 50 μL of XTT labeling mixture (XTT-labeling reagent:electron-coupling reagent=50:1 to reach a final XTT concentration of 0.3 mg/mL) was added to each well and the plates were incubated at 37°C in a 5% CO~2~ atmosphere for 4 h. Absorbance was measured with an enzyme-linked immunosorbent assay plate reader at 450 nm.

RNA isolation and quantitative real-time polymerase chain reaction (PCR) analysis
---------------------------------------------------------------------------------

Total RNA was extracted from cells using an easy-BLUE kit (the TRIzol reagent, iNtRON, Seongnam, Korea), according to the manufacturer's protocol. TRIzol was removed by the addition of chloroform and mRNA was precipitated with isopropanol. RNA precipitates were washed with 75% ethanol. Optical densities at 260 and 280 nm were measured using a UV spectrometer to assess RNA quantity and purity, and RNA integrity was confirmed by agarose gel electrophoresis. Gene-specific primers were designed to amplify human tyrosinase (TYR), Tumor necrosis factor α (TNF), interleukin 6 (IL6) and the housekeeping gene glyceralde-hyde 3-phosphate dehydrogenase (GAPDH) for an internal control. The following primer pairs were used for TYR (F: 5′-GCCAACGATCCTAT CTTCCTTC-3′, R: 5′-GTGCATTGGCTTCTGGATAAAC-3′), TNF (F: 5′-GAGGCCAAGCCCTGGTATG-3′, R: 5′-CGGGCCGATTGATCTCAG C-3′), IL6 (F: 5′-CTGGATTCAATGAGGAGACTTG-3′ R: 5′-CACTACTCTCAAATCTGTTCTGG-3′) and GAPDH (F: 5′-GTGATGGCATGGACTGTGGT-3′, R: 5′-AAGGGTCATCATCTCTGCCC-3′). All amplifications were conducted using a pre-mixture (20 μL) containing 500 nmol/L of gene-specific primers and 2 μL of template RNA under the following conditions: denaturation at 95°C for 1 min, followed by 45 cycles of 95°C for 20 s, 58°C for 20 s, and 72°C for 25 s, with a final extension at 72°C for 5 min.

Statistical analysis
--------------------

Graphical data are presented as mean ± SD. Statistical significance among triplicates and between groups were determined using one-or two-way analysis of variance (ANOVA) followed by a Bonferroni multiple comparisons post-test or Student's *t*-test, respectively. Significance was assumed when *p*\<0.05.

RESULTS
=======

Design of human tyrosinase siRNAs
---------------------------------

To build an efficient siRNA pool targeting human tyrosinase, we applied bioinformatics tools combining several advanced prediction models. We obtained the mRNA reference sequence (Refseq id NM_000372) from NCBI nucleotide dataset for human tyrosinase and excluded 5′UTR and 3′UTR regions from the prediction, because they can interfere with RISC function ([@b6-bt-26-282]). First, the sequence was evaluated for RISC accessibility to the target site using *RNAxs* software, which is considered an important factor for restricting RISC's endonucleolytic activity ([@b28-bt-26-282]). Beside target accessibility, this algorithm also evaluates self-folding energy and sequence asymmetry to calculate scores. From this algorithm, 272 19-mer double stranded sequences (17% of 1,572 sequences) passed the default threshold. Sequences were also evaluated by two second generation algorithms based on linear regression models: *i-Score* (inhibitory--Score) ([@b14-bt-26-282]) and *siRNA scales* ([@b18-bt-26-282]). Both *i-Score* and *siRNA scales* algorithms consider nucleotide position-dependent preference. *siRNA scales* calculates local duplex stability and total G/C content for evaluation of functional siRNAs. We applied filters for *i-Score* ≥65 and for *siRNA scales* ≤30, with whole ΔG≥−34.6 kcal/mol. We found that *i-Score* was more strict, passing 191 sequences (12%), whereas *siRNA scales* was less strict, passing 47% of sequences. Finally, 71 siRNAs were obtained that met the criteria of all three siRNA design algorithms. When whole ΔG value limitations were applied, only 34 siRNAs (2.2%) finally passed without off-target effects, as determined by using the NCBI nucleotide database ([Fig. 1A, 1B](#f1-bt-26-282){ref-type="fig"}). For this study, we designed 19-bp RNA duplexes with an asymmetric 2-nt overhang at the 3′ end of the antisense strand for better performance as suggested ([Fig. 1C](#f1-bt-26-282){ref-type="fig"}) ([@b22-bt-26-282]; [@b23-bt-26-282]). The full siRNA sequences are listed in [Table 1](#t1-bt-26-282){ref-type="table"}.

Evaluation of tyrosinase siRNA efficacy in the human melanoma cell line MNT-1
-----------------------------------------------------------------------------

To evaluate the efficacy of siRNAs selected by siRNA design tools, we transfected MNT-1 cells with 34 individual siR-NAs and measured tyrosinase mRNA (*TYR*) expression by qRT-PCR. As shown in the experimental scheme described in [Fig. 2A](#f2-bt-26-282){ref-type="fig"}, tyrosinase mRNA expression levels were measured on day 2 after transfection. The 34 siRNAs reduced tyrosinase mRNA levels by an average of 57.8% (SD=0.141) in the first screening. 13 siRNAs were more effective than the commercially available siRNA, which was used as positive control (P.C.) with significance ([Fig. 2B](#f2-bt-26-282){ref-type="fig"}, [Table 2](#t2-bt-26-282){ref-type="table"}). We further quantified tyrosinase mRNA to confirm the efficacy of the 6 most effective (\#16, 17, 23, 26, 28, and 31) and 3 least effective (\#2, 3, and 5) siRNAs. In accordance with the first screening, the 6 most effective siRNAs knocked down tyrosinase expression efficiently (0.294-fold vs. N.C.) and also were more effective than the positive control (0.39-fold vs. N.C.), whereas the 3 least effective siRNAs showed similar or lower efficacy ([Fig. 3A, 3B](#f3-bt-26-282){ref-type="fig"}). In the second screening, even the least effective siRNAs knocked down tyrosinase expression approximately 0.5-fold. To see if siRNAs decrease tyrosinase protein level, we performed immunoblot analysis. In accordance with the result from mRNA levels, tyrosinase protein level was decreased effectively ([Fig. 3C](#f3-bt-26-282){ref-type="fig"}). Generally, the 6 most effective siRNAs showed better performance than the 3 least effective ones. Considering the effective knockdown provided by even our worst-performing siRNAs, our results support the idea that siRNA production by combining multiple siRNA design algorithms was an efficient approach.

Anti-melanogenic effect of siRNAs in MNT-1 cells
------------------------------------------------

The above results indicate that the siRNAs we designed could downregulate melanin synthesis in melanin-producing cells. To test the effect of our siRNAs (\#16, 17, 26) on melanin synthesis by tyrosinase, we measured melanin content in siRNA-transfected MNT-1 cells. As shown in [Fig. 4A (upper)](#f4-bt-26-282){ref-type="fig"}, melanin content was only minimally changed on day 2 after transfection. However, when melanin content was analyzed on day 7, the anti-melanogenic effect of these siRNAs was detected ([Fig. 4A, lower](#f4-bt-26-282){ref-type="fig"}). Colorimetric measurement of these samples (day 7) indicated that all siRNAs significantly reduced melanin content (*p*\<0.001). siRNAs \#16 and 17 were as effective as the positive control in reducing melanin content by approximately 0.55-fold (0.56-fold by P.C.) although siRNA \#26 was less effective (∼0.74-fold) ([Fig. 4B](#f4-bt-26-282){ref-type="fig"}). These data show that the siRNAs we designed are effective in reducing melanin synthesis in cells.

The effect of siRNAs on cell viability
--------------------------------------

Some siRNAs result in toxicity, affecting cell viability by off-target effects related to cell growth, death, and other properties. To identify if these siRNAs result in cell toxicity, we analyzed cell viability by observing changes in cell morphology and by XTT assays in siRNA-transfected MNT-1 cells. On day 1 or 2 after siRNA transfection (\#16, 17, 26, and P.C.), no significant change in cell morphology was observed ([Fig. 5A](#f5-bt-26-282){ref-type="fig"}). Additionally, no discernible change in cell viability was seen as measured by XTT assay ([Fig. 5B](#f5-bt-26-282){ref-type="fig"}). We further tested if these siRNAs can induce immune response by measuring mRNA levels of TNFα and IL-6. siRNA \#16 and 17 had no effect on TNFα mRNA expression while \#26 showed increase around 1.8-fold in both naked and liposome aided conditions ([Fig. 5C](#f5-bt-26-282){ref-type="fig"}). However, the level was not higher than that of positive control (P.C.). In contrast, IL-6 was upregulated by all three siRNAs in liposome aided condition while the positive control showed no harmful effect. Especially, siRNA \#26 and P.C. triggered immune responses even in naked state, in which no reduction of tyrosinase mRNA was detected. Altogether, our data showed that combining siRNA design algorithms is an efficient approach for developing novel siRNA sequences. In addition, the selected siRNAs (\#16 and 17) were effective in suppressing synthesis of human melanin, suggesting that these siRNAs could be further developed as novel siRNA sequences for use in biomedical research and cosmetic fields.

DISCUSSION
==========

Skin-lightening agents are useful for cosmetic purposes and many such formulations have been developed for decades. Currently, various agents are available, with diverse mechanisms of action such as tyrosinase inhibition (hydroquinone, azelaic acid, arbutin), stimulation of keratinocyte turnover and reduction of melanosome transfer (retinoids), copper chelation (kojic acid and ascorbic acid), and inhibition of melanosome maturation (arbutin) ([@b26-bt-26-282]). Tyrosinase is a rate-limiting enzyme in melanin production from melanocytes ([@b17-bt-26-282]; [@b11-bt-26-282]). Here, we sought to reduce tyrosinase expression by applying tyrosinase siRNAs designed using multiple prediction tools.

Efficient siRNA design is crucial, as even subtle sequence changes may significantly alter functionality. Currently, numerous siRNA design algorithms have been developed and these algorithms consider diverse factors to be critical for functionality, such as target accessibility, secondary mRNA structures, and positional preferences of siRNA sequence. Early studies on rules for preferred siRNA sequence patterns were suggested: N2SN17WN2 by Ui-Tei rule ([@b29-bt-26-282]), N4AN6TN2HN5WN2 by Reynolds ([@b21-bt-26-282]) and so on. These rules also commonly indicate that an asymmetrical siRNA structure is critical: more A/U bases are necessary at the 5′-end of the antisense strand whereas more G/C bases are necessary at the 5′-end of the sense strand. Low GC content in the 5′-end of the antisense strand is considered to aid in unwinding and incorporation of the siRNA duplex into the RISC complex.

*i-Score* and *siRNA scales* algorithms calculate nucleotide preference at each position of siRNA in addition to other factors. For that reason, scores from *i-Score* and *siRNA scales* algorithms showed a mild to moderate correlation (R^2^=0.4309) (data not shown) and most siRNAs that passed the requirements of the *i-Score* algorithm were included in *siRNA scales*. Our results also showed that the default threshold provided by *siRNA scales* is less strict than *i-Score* (47% vs. 12% from total).

Previous studies suggested that the siRNA secondary structure whole ΔG values are a critical determinant in siRNA efficiency ([@b14-bt-26-282]; [@b16-bt-26-282]). Especially, siRNAs with ΔG values less than −34.6 kcal/mol, which are thermodynamically stable, showed poor knockdown efficiency ([@b14-bt-26-282]). When we calculated the correlation coefficient between ΔG values and suppression levels using our data, no significant correlation was observed (data not shown). However, since we only examined a small number of siRNAs, we cannot conclude that ΔG values are statistically unrelated to siRNA efficiency. To clearly determine the effect of whole ΔG values on siRNA activity, a large number of samples is needed and siRNAs with lower whole ΔG values should be added in the test for comparison.

Collectively, we designed human tyrosinase siRNAs using multiple algorithms and parameters and identified highly efficient siRNAs that may be useful in the cosmetic field. In fact, many siRNAs are currently being considered for use in biomedicine and cosmetic fields, and have been tested in clinical trials worldwide. However, for the broad usage of siRNA-based applications, some barriers remain to be resolved such as issues with safety, stability, and delivery.

This study was supported by a grant from Leaders Cosmetics, Sansung L&S Co., Ltd (\#2015/05/20-31) and by Basic Science Research Program through the National Research Foundation of Korea (KRF) funded by the Ministry of Education (2016R1D1A1B01012515).

![Experimental scheme for selecting the best tyrosinase-targeted siRNAs. (A) Tyrosinase mRNA sequence was obtained from NCBI nucleotide dataset (Refseq id NM_000372). siRNAs were filtered from *RNAxs* using default parameters and then further selected according to the scores acquired from *i-Score* ≥65 and *siRNA scales* ≤30 prediction softwares, with whole ΔG values ≥-34.6 kcal/mol. (B) Distribution diagram of selected siRNAs according to the algorithms used. Numbers indicate siRNA identity. Percentages represent the population of siRNA from total number of tested siRNAs. (C) The structure of siRNA. Sense strands have 19 nt while antisense strands have 19+2 nt skeletons. 3′ end overhangs were designed only for the antisense strand.](bt-26-282f1){#f1-bt-26-282}

![Screening for optimal tyrosinase siRNA sequences. (A) Experimental scheme of the study. (B) MNT-1 cells were transfected with siRNAs for negative control (N.C.), positive control (P.C. \#1) or tyrosinase (\#1 to \#34). The relative expression level of tyrosinase 2 days after transfection is presented as a bar graph. ^\*^Indicates the 13 siRNAs showing higher knockdown efficiency than the positive control (P.C. \#1). Significant difference was determined by one way ANOVA. Data are shown as means ± SD.](bt-26-282f2){#f2-bt-26-282}

![Effective anti-melanogenesis by tyrosinase siRNA sequence. MNT-1 cells were transfected with siRNA for negative control (N.C.), positive control (P.C.), or tyrosinase (top 6 siRNAs and bottom 3 siRNAs among the 34 siRNA candidates) for a second screening. (A) The relative expression level of tyrosinase at day 2 after transfection is presented as a bar graph. Data are means ± SD. ^\#^ indicates the top 3 siRNAs with highest knockdown efficiency. Significant difference was determined by one way ANOVA. (B) Average expression levels compared to the negative control siRNA (N.C.) are presented. ^\*\*^*p*\<0.01; ^\*\*\*^*p*\<0.001 versus positive control. (C) Tyrosinase protein level was measured by immunoblot analysis using anti-tyrosinase antibody. GAPDH was used as a loading control.](bt-26-282f3){#f3-bt-26-282}

![Anti-melanogenic effect of the top 3 siRNAs. (A) Images of the cell pellet at day 2 (upper) and 7 (lower) after siRNA transfection. (B) The melanin content from the cell pellet of at day 7 after siRNA transfection is shown as a bar graph. Images of melanin level after each siRNA transfection are shown (upper). Data are shown as means ± SD.](bt-26-282f4){#f4-bt-26-282}

![Negligible effects of siRNA transfection on proliferation. (A) microscopic images of MNT-1 cells at day 1 (upper panels) and day 2 (lower panels) after the indicated siRNA transfection. (B) Cell viability after transfection with the indicated siRNA was determined at days 1, 2, and 3. Data are shown as means ± SD. (C) mRNA expression of Tyrosinase, TNFa and IL6 after siRNA transfection with or without transfection reagent was measured with real-time PCR (N.C.: negative control, and P.C.: positive control). Data are shown as means ± SD.](bt-26-282f5){#f5-bt-26-282}

###### 

Selected siRNA sequences for human tyrosinase (NM_000372)

       position   sense                 Antisense               *siRNA scales*   *i-Score*   Whole ΔG
  ---- ---------- --------------------- ----------------------- ---------------- ----------- ----------
  1    241        CCUUCCGUCUUUUAUAAUA   UAUUAUAAAAGACGGAAGGcc   11               75.0        −30.8
  2    412        CUCACUUUAGCAAAGCAUA   UAUGCUUUGCUAAAGUGAGgu   11               71.2        −33.4
  3    464        CCUAUGGCCAAAUGAAAAA   UUUUUCAUUUGGCCAUAGGuc   9                71.9        −33.0
  4    471        CCAAAUGAAAAAUGGAUCA   UGAUCCAUUUUUCAUUUGGcc   20               70.1        −30.9
  5    472        CAAAUGAAAAAUGGAUCAA   UUGAUCCAUUUUUCAUUUGgc   11               70.7        −28.5
  6    485        GAUCAACACCCAUGUUUAA   UUAAACAUGGGUGUUGAUCca   6                75.9        −33.5
  7    494        CCAUGUUUAACGACAUCAA   UUGAUGUCGUUAAACAUGGgu   0                80.5        −32.6
  8    495        CAUGUUUAACGACAUCAAU   AUUGAUGUCGUUAAACAUGgg   12               70.9        −30.4
  9    498        GUUUAACGACAUCAAUAUU   AAUAUUGAUGUCGUUAAACau   20               69.5        −28.4
  10   500        UUAACGACAUCAAUAUUUA   UAAAUAUUGAUGUCGUUAAac   24               67.0        −27.5
  11   510        CAAUAUUUAUGACCUCUUU   AAAGAGGUCAUAAAUAUUGau   12               74.7        −29.1
  12   582        CUGGAGAGACAUUGAUUUU   AAAAUCAAUGUCUCUCCAGau   19               67.6        −33.5
  13   679        GGAGAUGAAAACUUCACUA   UAGUGAAGUUUUCAUCUCCug   2                75.2        −33.8
  14   680        GAGAUGAAAACUUCACUAU   AUAGUGAAGUUUUCAUCUCcu   15               69.7        −31.6
  15   681        AGAUGAAAACUUCACUAUU   AAUAGUGAAGUUUUCAUCUcc   27               69.7        −30.1
  16   852        CCAUCAGUCUUUAUGCAAU   AUUGCAUAAAGACUGAUGGcu   8                69.2        −33.6
  17   856        CAGUCUUUAUGCAAUGGAA   UUCCAUUGCAUAAAGACUGau   4                79.5        −33.4
  18   966        GAGUUUGACCCAAUAUGAA   UUCAUAUUGGGUCAAACUCag   3                74.7        −33.7
  19   967        AGUUUGACCCAAUAUGAAU   AUUCAUAUUGGGUCAAACUca   20               65.9        −32.4
  20   1016       GCUUUAGAAAUACACUGGA   UCCAGUGUAUUUCUAAAGCug   11               67.2        −33.7
  21   1017       CUUUAGAAAUACACUGGAA   UUCCAGUGUAUUUCUAAAGcu   9                73.0        −31.2
  22   1022       GAAAUACACUGGAAGGAUU   AAUCCUUCCAGUGUAUUUCua   7                69.4        −33.7
  23   1094       CCUUGCACAUCUAUAUGAA   UUCAUAUAGAUGUGCAAGGca   7                75.1        −34.0
  24   1099       CACAUCUAUAUGAAUGGAA   UUCCAUUCAUAUAGAUGUGca   16               66.3        −32.0
  25   1168       CAUGCAUUUGUUGACAGUA   UACUGUCAACAAAUGCAUGgu   10               66.4        −33.3
  26   1171       GCAUUUGUUGACAGUAUUU   AAAUACUGUCAACAAAUGCau   12               71.1        −30.9
  27   1173       AUUUGUUGACAGUAUUUUU   AAAAAUACUGUCAACAAAUgc   26               67.6        −27.2
  28   1305       UGGUGAUUUCUUUAUUUCA   UGAAAUAAAGAAAUCACCAuu   21               71.0        −30.0
  29   1306       GGUGAUUUCUUUAUUUCAU   AUGAAAUAAAGAAAUCACCau   8                76.1        −29.0
  30   1338       CUAUGACUAUAGCUAUCUA   UAGAUAGCUAUAGUCAUAGcc   14               74.5        −32.8
  31   1372       GACUCUUUUCAAGACUACA   UGUAGUCUUGAAAAGAGUCug   10               68.8        −33.7
  32   1375       UCUUUUCAAGACUACAUUA   UAAUGUAGUCUUGAAAAGAgu   15               67.4        −30.3
  33   1376       CUUUUCAAGACUACAUUAA   UUAAUGUAGUCUUGAAAAGag   11               70.8        −28.8
  34   1572       GUAUCAGAGCCAUUUAUAA   UUAUAAAUGGCUCUGAUACaa   11               74.7        −32.0

34 siRNA sequences were selected that passed the thresholds from target accessibility evaluation, *i-Score*, *siRNA scales*, and ΔG.

###### 

Relative expression level of tyrosinase mRNA after siRNA transfection

  siRNA \#   Test 1   Test 2   Mean   Order of efficiency   Second test
  ---------- -------- -------- ------ --------------------- -------------
  N.C.       1.00     0.98     0.99                         
  P.C.       0.58     0.56     0.57                         
  1          0.70     0.59     0.65   25                    
  2          0.87     0.81     0.84   34                    \*
  3          0.80     0.80     0.80   32                    \*
  4          0.62     0.66     0.64   24                    
  5          0.77     0.84     0.80   33                    \*
  6          0.80     0.73     0.77   31                    
  7          0.76     0.76     0.76   29                    
  8          0.64     0.61     0.62   21                    
  9          0.75     0.73     0.74   27                    
  10         0.54     0.46     0.50   13                    
  11         0.62     0.60     0.61   20                    
  12         0.67     0.66     0.67   26                    
  13         0.63     0.64     0.63   22                    
  14         0.59     0.58     0.59   18                    
  15         0.42     0.47     0.45   8                     
  16         0.40     0.41     0.40   2                     \*
  17         0.41     0.44     0.43   6                     \*
  18         0.61     0.66     0.63   23                    
  19         0.51     0.51     0.51   15                    
  20         0.59     0.58     0.59   19                    
  21         0.52     0.55     0.54   17                    
  22         0.79     0.73     0.76   30                    
  23         0.52     0.28     0.40   3                     \*
  24         0.73     0.77     0.75   28                    
  25         0.47     0.42     0.44   7                     
  26         0.43     0.38     0.41   4                     \*
  27         0.49     0.42     0.45   9                     
  28         0.42     0.35     0.39   1                     \*
  29         0.47     0.46     0.47   10                    
  30         0.53     0.53     0.53   16                    
  31         0.42     0.40     0.41   5                     \*
  32         0.50     0.49     0.50   12                    
  33         0.49     0.53     0.51   14                    
  34         0.48     0.48     0.48   11                    

Average relative expression level compared to the negative control siRNA (N.C.) were presented.

[^1]: The first two authors contributed equally to this work.
